Work

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Year: 2021

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.21.01935

Authors: Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander

Institutions: University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Medical College of Wisconsin, Oregon Health & Science University, Vanderbilt University Medical Center, University of Wisconsin–Madison

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200312283

FWCI: 29.13

Cites: 33

Cited by: 267

Related to: 10